Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case -24% Improvement Relative Risk c19early.org/cbd Lehrer et al. Cannabidiol for COVID-19 Prophylaxis Does cannabidiol reduce COVID-19 infections? Retrospective study in the United Kingdom (March - April 2020) More cases with cannabidiol (p=0.009) Lehrer et al., Chronic Diseases and Translationa.., doi:10.1002/cdt3.38 Favors cannabidiol Favors control
Association of cannabis with chronic obstructive pulmonary disease and COVID-19 infection
Lehrer et al., Chronic Diseases and Translational Medicine, doi:10.1002/cdt3.38
Lehrer et al., Association of cannabis with chronic obstructive pulmonary disease and COVID-19 infection, Chronic Diseases and Translational Medicine, doi:10.1002/cdt3.38
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
UK Biobank retrospective showing a higher risk of COVID-19 cases with a history of cannabis use.
risk of case, 23.8% higher, OR 1.24, p = 0.009, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lehrer et al., 22 Jun 2022, retrospective, United Kingdom, peer-reviewed, mean age 57.0, 3 authors, study period 16 March, 2020 - 26 April, 2020.
Contact: stevenlehrer@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Abstract: Received: 14 April 2022 | Accepted: 7 June 2022 DOI: 10.1002/cdt3.38 BRIEF REPORT Association of cannabis with chronic obstructive pulmonary disease and COVID‐19 infection Steven Lehrer1 | Peter H. Rheinstein2 1 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA 2 Severn Health Solutions, Severna Park, Maryland, USA Correspondence: Steven Lehrer, Mt Sinai Medical Center, Box 1236 Radiation Oncology, 1 Gustave L. Levy Pl, New York, NY 10029, USA. Email: stevenlehrer@hotmail.com Edited by: Yi Cui Funding information Office of Research Infrastructure of the National Institutes of Health, Grant/Award Number: S10OD018522, S10OD026880 K E Y W O R DS cannabis, COPD, COVID‐19, lungs, tobacco In a 2012 study, occasional and low cumulative cannabis use was not associated with adverse effects on pulmonary function.1 With tobacco, the more used, the more loss of air flow rate and lung volume. The same was not true with cannabis use. Air flow rate increased rather than decreased with increased exposure to cannabis up to a certain level. An important factor that helped explain the difference in effects from tobacco and cannabis was the amount of each that was smoked. Tobacco users typically smoked 10–20 cigarettes daily, some even more. Cannabis smokers, on average, smoked only two to three times a month, so the average exposure to cannabis was much lower than for tobacco. People experiment with cannabis in their late teens and 20s, and some consume relatively low levels for years. Although heavy exposure to cannabis might damage the lungs, reliable estimates of the effects of heavy use were not available in the 2012 study, as heavy users were relatively rare in the study population. In the current analysis, we used data from UK Biobank (UKB) to assess the effect of cannabis on coronavirus disease (COVID‐19) infection and to determine whether cannabis lung damage might facilitate COVID‐19 infection in formerly heavy users. The UKB is a large prospective observational study comprising about 500,000 men and women (N = 229,134 men, N = 273,402 women), more than 90% White, aged 40–69 years at enrollment. Participants were recruited from across 22 centers located throughout England, Wales, and Scotland, between 2006 and 2010, and continue to be longitudinally followed for capture of subsequent health events.2 This methodology is like that of the Framingham Heart Study,3 with the exception that the UKB program collects postmortem samples, which Framingham did not. Our UKB application was approved as UKB project 57,245 (S.L. and P.H.R.). Doctor‐diagnosed chronic obstructive pulmonary disease (COPD) is from UKB data field 22,130. At enrollment, the subject was asked on a touchscreen, “Has a doctor ever told you that you have had any of the conditions below?” COPD (Chronic Obstructive Pulmonary Disease) was one of the options listed. The subject was asked, “Have you taken cannabis (marijuana, grass, hash, ganja, blow, draw, skunk, weed, spliff, dope), even if it was a long time ago?” If the answer was “yes,” cannabis use was recorded in the UKB data field 20,454, maximum frequency of taking cannabis, question asked: “Considering when you were taking cannabis most regularly, how often did you take it?” Answers were 1 = Less than once a month, 2 = Once a month or more, but not every week, 3 = Once a week or more, but not every day, and 4 = Every day. Subject was then asked (UKB data field 20455) “About how old..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit